Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Clear Secure Inc (YOU) Price & Performance

Eli Lilly And CoTrade
Clear Secure IncTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Clear Secure Inc — how do they compare? Eli Lilly And Co trades at $1,224.27 (market cap $1.08T), while Clear Secure Inc trades at $47.14 (market cap $4.98B). The key difference: Eli Lilly And Co is far larger — about 216.9× Clear Secure Inc's market cap, and Clear Secure Inc pays the higher dividend (1.19%). Which is the better fit depends on your goals.

LLYYOU
Market Cap
$1.08T$4.98B
Sector
HealthTechnology
52-Week High
$1.24K$62.36
52-Week Low
$639.43$29.61
Enterprise Value
$1.13T$4.13B
Dividend Yield
0.57%1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Clear Secure Inc

Clear Secure (YOU) trades at $47.31, down 7.63% over 24 hours, reflecting a bearish technical trend with support near $45. Fundamentally, the company reported strong Q2 2026 earnings of $0.49 per share, beating estimates, with revenue growth to $1.0 billion projected for 2026 and a net income margin of 14.78%. Recent news highlights expansion of its CLEAR1 platform and corporate membership launches, driving investor optimism despite recent price pressure.

The outlook is mixed: robust earnings beats and strategic initiatives support growth, but high valuation ratios (P/E of 32.62) and bearish technical signals pose risks. Analysts are divided with a 44% buy rating, suggesting cautious optimism amid volatility. Key risks include execution challenges and competitive pressures in identity verification services.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Clear Secure Inc

Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.

Read more on YOU